Multifocal primary neuroblastoma tumor heterogeneity in siblings with co‐occurring PHOX2B and NF1 genetic aberrations
Sign Up to like & getrecommendations! Published in 2019 at "Genes"
DOI: 10.1002/gcc.22809
Abstract: Neuroblastoma, the most common extracranial solid tumor of childhood, can present in multiple primary sites, but the extent of genetic heterogeneity among tumor foci, as well as the presence or absence of common oncogenic drivers,… read more here.
Keywords: genetic aberrations; heterogeneity; phox2b nf1; neuroblastoma ... See more keywords
Fructose milieu undermines the therapeutic effect of Tribulus terrestris extract on neuroblastoma cell line via maintaining mitochondrial function
Sign Up to like & getrecommendations! Published in 2022 at "Environmental Toxicology"
DOI: 10.1002/tox.23632
Abstract: Fructose overconsumption promotes tumor progression. Neuroblastoma is a common extracranial tumor with about 50% 5‐year survival rate in high‐risk children. The anti‐tumor effect of Tribulus terrestris might bring new hope to neuroblastoma therapy. However, whether… read more here.
Keywords: cell; therapeutic effect; neuroblastoma; terrestris extract ... See more keywords
Polyphyllin D, a steroidal saponin in Paris polyphylla, induces apoptosis and necroptosis cell death of neuroblastoma cells
Sign Up to like & getrecommendations! Published in 2017 at "Pediatric Surgery International"
DOI: 10.1007/s00383-017-4069-4
Abstract: PurposeNeuroblastoma is a refractory pediatric malignant solid tumor. The previous studies demonstrated that Polyphyllin D, the main constituent of Paris polyphylla, a traditional Chinese medicine, exerts an anti-tumor effect on many tumors. However, its effects… read more here.
Keywords: neuroblastoma; cell death; cell; paris polyphylla ... See more keywords
Potential anti-neuroblastoma agents from Juniperus oblonga.
Sign Up to like & getrecommendations! Published in 2019 at "Biochemical and biophysical research communications"
DOI: 10.1016/j.bbrc.2019.06.123
Abstract: Neuroblastoma (NB) is a neuroendocrine tumor derived from neural crest cells. Approximately 90% of cases occur in children less than 5 years old. The amplification of MYCN correlates with high-risk neuroblastoma and patients with MYCN… read more here.
Keywords: cell; neuroblastoma; potential anti; anti neuroblastoma ... See more keywords
The role of the ShcD and RET interaction in neuroblastoma survival and migration
Sign Up to like & getrecommendations! Published in 2018 at "Biochemistry and Biophysics Reports"
DOI: 10.1016/j.bbrep.2018.01.007
Abstract: Preliminary screening data showed that the ShcD adaptor protein associates with the proto-oncogene RET receptor tyrosine kinase. In the present study, we aimed to investigate the molecular interaction between ShcD and RET in human neuroblastoma… read more here.
Keywords: role shcd; shcd; shcd ret; neuroblastoma ... See more keywords
The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model.
Sign Up to like & getrecommendations! Published in 2017 at "Cancer letters"
DOI: 10.1016/j.canlet.2017.04.022
Abstract: Activating germline mutations of anaplastic lymphoma kinase (ALK) occur in most cases of hereditary neuroblastoma (NB) and the constitutively active kinase activity of ALK promotes cell proliferation and survival in NB. Therefore, ALK kinase is… read more here.
Keywords: alk; apoptosis; neuroblastoma; alectinib ... See more keywords
The small molecule inhibitor YK-4-279 disrupts mitotic progression of neuroblastoma cells, overcomes drug resistance and synergizes with inhibitors of mitosis
Sign Up to like & getrecommendations! Published in 2017 at "Cancer Letters"
DOI: 10.1016/j.canlet.2017.05.027
Abstract: Neuroblastoma is a biologically and clinically heterogeneous pediatric malignancy that includes a high-risk subset for which new therapeutic agents are urgently required. As well as MYCN amplification, activating point mutations of ALK and NRAS are… read more here.
Keywords: inhibitor; high risk; small molecule; neuroblastoma ... See more keywords
The inhibition of GHR enhanced cytotoxic effects of etoposide on neuroblastoma.
Sign Up to like & getrecommendations! Published in 2021 at "Cellular signalling"
DOI: 10.1016/j.cellsig.2021.110081
Abstract: Etoposide, a DNA damage-inducing agent, is widely used to treat neuroblastoma. Etoposide binds to and inhibits topoisomerase II, thereby inducing the DNA damage response. However, the underlying mechanism of etoposide resistance in neuroblastoma remains unclear.… read more here.
Keywords: cell viability; effects etoposide; etoposide resistance; neuroblastoma ... See more keywords
CD44-high neural crest stem-like cells are associated with tumour aggressiveness and poor survival in neuroblastoma tumours
Sign Up to like & getrecommendations! Published in 2019 at "EBioMedicine"
DOI: 10.1016/j.ebiom.2019.10.041
Abstract: Background Neuroblastoma is a paediatric tumour originated from sympathoadrenal precursors and characterized by its heterogeneity and poor outcome in advanced stages. Intra-tumoral cellular heterogeneity has emerged as an important feature in neuroblastoma, with a potential… read more here.
Keywords: crest stem; neuroblastoma; stem like; cd44 ... See more keywords
Ellipticine-loaded apoferritin nanocarrier retains DNA adduct-based cytochrome P450-facilitated toxicity in neuroblastoma cells.
Sign Up to like & getrecommendations! Published in 2019 at "Toxicology"
DOI: 10.1016/j.tox.2019.03.009
Abstract: Although ellipticine (Elli) is an efficient anticancer agent, it exerts several adverse effects. One approach to decrease the adverse effects of drugs is their encapsulation inside a suitable nanocarrier, allowing targeted delivery to tumour tissue… read more here.
Keywords: neuroblastoma; cells ellipticine; cytochrome p450; ellipticine ... See more keywords
Proteomic Signature of Neuroblastoma Cells UKF-NB-4 Reveals Key Role of Lysosomal Sequestration and the Proteasome Complex in Acquiring Chemoresistance to Cisplatin.
Sign Up to like & getrecommendations! Published in 2019 at "Journal of proteome research"
DOI: 10.1021/acs.jproteome.8b00867
Abstract: Cisplatin (CDDP) is a widely used agent in the treatment of neuroblastoma. Unfortunately, the development of acquired chemoresistance limits its clinical use. To gain a detailed understanding of the mechanisms underlying the development of such… read more here.
Keywords: proteasome complex; chemoresistance; cisplatin; neuroblastoma ... See more keywords